The PharmD/MD Dual-Degree Program and Its Potential Value in the Pharmaceutical Industry

Khushbu S. Shah, Upasana Marwah, Kristina Bundra, Carol S. Goldin, Michael Toscani, Joseph Barone, John Colaizzi

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The first dual-degree program combining both the doctor of pharmacy (PharmD) and the doctor of medicine (MD) degrees was designed and launched by Rutgers, The State University of New Jersey, in academic year 2013-2014. This joint effort was led by the Ernest Mario School of Pharmacy (EMSOP) and the Robert Wood Johnson Medical School (RWJMS) to combine expertise in both diagnostic and treatment facets of health care and to prepare graduates for leadership roles in providing and managing comprehensive patient care in a variety of settings. One area of potential value of these skill sets is the drug development industry. A survey was conducted among pharmaceutical executive stakeholders associated with a postdoctoral training program to assess the perceived value of this new dual-degree skill set and to identify particular functions where the combined training has its best fit. Results indicate that the combined nature of this training is highly valued in this setting, especially in the areas of clinical pharmacology, drug safety and pharmacovigilance, medical affairs/strategy, and medical science liaisons. Future monitoring of graduates will further define the value of this dual degree in this and other health care settings.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalTherapeutic Innovation and Regulatory Science
Volume50
Issue number6
DOIs
StatePublished - Nov 1 2016

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Keywords

  • PharmD/MD
  • drug development
  • dual degree
  • pharma
  • pharmaceutical industry

Cite this